Shares of Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) fell 2.8% during trading on Wednesday . The company traded as low as $8.16 and last traded at $8.26. 334,673 shares traded hands during trading, a decline of 1% from the average session volume of 337,931 shares. The stock had previously closed at $8.50.
Silverback Therapeutics Price Performance
The firm has a market cap of $301.08 million, a PE ratio of -3.45 and a beta of 0.60. The business’s 50 day moving average price is $8.84 and its 200 day moving average price is $6.40.
About Silverback Therapeutics
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Recommended Stories
- Five stocks we like better than Silverback Therapeutics
- Stock Market Sectors: What Are They and How Many Are There?
- 3 Stocks Leading the U.S. Agriculture Comeback
- Upcoming IPO Stock Lockup Period, Explained
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Canadian Penny Stocks: Can They Make You Rich?
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
